Rare but relevant: Nitrous oxide and peripheral neurotoxicity, what do we know?
Where this comes from
- Record sourced from PubMed, PMID 39711181.
- Also identified by DOI 10.1111/add.16753 and PMC identifier 11986278.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nitrous oxide (N<sub>2</sub>O), used medically as an anaesthetic, has gained popularity as a recreational drug, with rising prevalence particularly among young adults. While its reinforcing and addictive potential remains debated, N<sub>2</sub>O is proven to be neurotoxic, especially with prolonged, heavy use, which is often unexpected for users. The neurotoxicological mechanism underlying N<sub>2</sub>O-induced neurotoxicity involves inactivation of vitamin B<sub>12</sub> (cobalamin), which disrupts methionine synthesis, essential for maintaining the myelin sheath. This can result in demyelinating diseases, including generalized demyelinating polyneuropathy (GDP). Clinical incidence of N<sub>2</sub>O-induced peripheral neuropathy is largely unknown, although some research suggests it is not uncommon. Treatment includes immediate cessation of N<sub>2</sub>O use and vitamin B<sub>12</sub> supplementation. Although this treatment often reverses damage, residual symptoms such as limb weakness may persist. Additionally, genetic and dietary factors, such as vitamin B<sub>12</sub> deficiency, may heighten individual vulnerability for N<sub>2</sub>O's detrimental effects.
Medical subject headings
- Nitrous Oxide
- Peripheral Nervous System Diseases
- Neurotoxicity Syndromes
- Anesthetics, Inhalation